针对慢性心力衰竭的最佳利尿策略
Satoshi Shoji1, Martin Osorio Nader2, Robert J Mentz3
1Department of Medicine, Duke Clinical Research Institute, Durham, NC, USA; Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.
The Medical clinics of North America
|October 24, 2025
概括
循环利尿剂可以控制慢性心力衰竭的拥堵,但它们对生存的影响尚不清楚. 个性化监测和优化指南导向医学治疗 (GDMT) 是有效的利尿剂使用和改善患者治疗结果的关键.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 循环利尿剂推用于慢性心力衰竭 (CHF) 拥堵.
- 关于它们对CHF发病率和死亡率的影响的证据有限.
- 目前的指导方针主张使用最低有效剂量和个性化护理.
研究的目的:
- 探索优化循环利尿剂在CHF使用的策略.
- 突出个性化监控在CHF管理中的作用.
- 调查指南导向医疗疗 (GDMT) 与利尿剂管理的整合.
主要方法:
- 审查当前的指导方针和关于循环利尿剂在CHF使用的证据.
- 强调个性化监测,包括临床,生物标志物和血液动力学参数.
- 讨论优化GDMT组件,如RNA,SGLT2抑制剂和MRA等.
主要成果:
- 循环利尿剂对心血管疾病发病率和死亡率的确切影响需要进一步的大规模调查.
- 个性化患者监测对于有效的利尿剂管理至关重要.
- 优化GDMT可能使循环利尿剂剂量减少.
结论:
- 将优化的GDMT与量身定制的监测策略相结合,可以提高循环利尿剂的疗效.
- 通过个性化护理改善循环利尿剂管理可能会导致心血管衰竭的更好的临床结果.
- 需要进一步的研究来澄清循环利尿剂对CHF预后的长期影响.
相关概念视频
Heart Failure Drugs: Diuretics
796
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
796
Heart Failure V: Medical Management
215
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
215
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
928
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
928
Heart Failure VI: Adjunct Therapies
252
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
252
Antihypertensive Drugs: Action of Diuretics
2.2K
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
2.2K
Heart Failure Drugs: β-Blockers
760
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
760


